Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | SI | P14410 | 1/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8984370 | 0.90 | LTA4H (0.58) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| 1,4-Diisopentoxybenzene SCHEMBL2846102 | 0.89 | TDP1 (0.79) | TDP1MAPK1EPHX2GAAHTT | |
| SCHEMBL13721026 | 0.89 | LTA4H (0.53) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL13721025 | 0.89 | LTA4H (0.53) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL11231682 | 0.88 | LTA4H (0.55) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL8509157 | 0.87 | GAA (0.56) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL20603875 | 0.86 | NR5A1 (0.65) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL2050248 | 0.86 | ALOX5 (0.55) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL21157749 | 0.85 | RARB (0.60) | TDP1MAPK1EPHX2LTA4HNR5A1 | |
| SCHEMBL9637722 | 0.84 | LTA4H (0.52) | TDP1MAPK1EPHX2LTA4HNR5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104328110-A | Kit and method for extracting soil microorganism DNA (Deoxyribonucleic Acid) based on paramagnetic particle method | UNIV FUJIAN | 2015-02-04 | — | — | CN | claimed |
| CN-104293770-A | Kit and method for quickly extracting RNA (ribonucleic acid) of soil microorganisms | UNIV FUJIAN | 2015-01-21 | — | — | CN | claimed |
| EP-3126346-B1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-9896434-B2 | Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2018-02-20 | — | — | US | disclosed |
| EP-3126346-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170029405-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-02 | — | — | US | disclosed |
| US-9497963-B2 | Methods and compositions for control of gypsy moth, Lymantria dispar | SIMON FRASER UNIVERSITY (CA) | 2016-11-22 | — | — | US | disclosed |
| US-9497963-B2 | Methods and compositions for control of gypsy moth, Lymantria dispar | SIMON FRASER UNIVERSITY (CA) | 2016-11-22 | — | — | US | disclosed |
| CN-106132949-A | Substituted indone compound as the GPR119 regulator for the treatment of diabetes, obesity, dyslipidemia and associated conditions | 赛诺菲 | 2016-11-16 | — | — | CN | disclosed |
| EP-2906550-B1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015150563-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-10-08 | — | — | WO | disclosed |
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | MITSUI CHEMICALS, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1672626-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM | Mitsui Chemicals, Inc. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-0873881-B1 | Reversible thermochromic compositions | PILOT INK CO LTD (JP) | 2001-10-17 | — | — | EP | disclosed |
| CN-1059895-C | Method for preparing alkoxy substituted triphenylamine | MITSUI TOATSU CHEMICALS (JP) | 2000-12-27 | — | — | CN | disclosed |
| US-5919404-A | MIXTURE OF COLOR DEVELOPING COMPOUND AND ELECTRON ACCEPTORALKOXYPHENOL COMPOUND | THE PILOT INK CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0873881-A1 | Reversible thermochromic compositions | The Pilot Ink CO., Ltd. (JP) | 1998-10-28 | — | — | EP | disclosed |
| CN-1130174-A | Method for preparing alkoxy substituted triphenylamine | MITSUI TOATSU CHEMICALS (JP) | 1996-09-04 | — | — | CN | disclosed |
| EP-0353571-B1 | Phenoxyalkyl-substituted heteroaromates, process for their preparation and their use as pesticides | BASF AG (DE) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | CACNA1B, KCNN4, KCNN2 | TDP1 4127/4885MAPK1 657/4885EPHX2 4301/4885 |
| US-20170029405-A1 | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, INSR, GPR65 | TDP1 4630/4885MAPK1 1813/4885EPHX2 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.